Skip to content
DataLookout
Menu

NUVICOLNCT07870967

Undenatured Type II Collagen for Knee Osteoarthritis Pain

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Site details revised
    • Study description expanded, about 5 words
  2. Minor Secondary endpoints: 6 to 8
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change in joint pain intensity measured by visual analog scale
Timeframe: Baseline to 16 weeks

Secondary (8)

Change in knee-related quality of life measured by KOOS
Change in pain, stiffness, and physical function measured by the Western Ontario and McMaster Universities Osteoarthritis Index
Change in concomitant analgesic medication use
Change in knee muscle function by dynamometry
Change in serum cartilage oligomeric matrix protein concentration
Show 3 moreShow less
Change in renal and hepatic blood safety parameters
Change in urinary C-terminal telopeptide of type II collagen concentration
Incidence of adverse events

Arms and interventions

Nuvicol II (nuvicol® II)Experimental

Participants receive Nuvicol II (nuvicol® II), undenatured type II collagen from chicken source, 40 mg once daily for 4 months.

Nuvicol SII (nuvicol® S II)Experimental

Participants receive Nuvicol SII (nuvicol® S II), undenatured type II collagen from salmon source, 40 mg once daily for 4 months.

PlaceboPlacebo comparator

Participants receive matching placebo capsules containing maltodextrin and magnesium stearate once daily for 4 months.

Dietary supplements: Placebo, Nuvicol II, Nuvicol SII

Sites

1 site in 1 country

  • UCAM HiTech - Unidad de Estudios ClínicosMurcia, Murcia, Spain